WO2001090361A3 - Modulation of inflammation by protease-treated mcp-3 chemokine - Google Patents
Modulation of inflammation by protease-treated mcp-3 chemokine Download PDFInfo
- Publication number
- WO2001090361A3 WO2001090361A3 PCT/CA2001/000741 CA0100741W WO0190361A3 WO 2001090361 A3 WO2001090361 A3 WO 2001090361A3 CA 0100741 W CA0100741 W CA 0100741W WO 0190361 A3 WO0190361 A3 WO 0190361A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- host
- present
- methods
- inflammation
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001261971A AU2001261971A1 (en) | 2000-05-26 | 2001-05-25 | Modulation of inflammation by protease-treated mcp-3 chemokine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,307,705 | 2000-05-26 | ||
CA 2307705 CA2307705A1 (en) | 2000-05-26 | 2000-05-26 | Modulation of inflammation by protease products |
CA002316405A CA2316405A1 (en) | 2000-05-26 | 2000-08-17 | Modulation of inflammation by protease products |
CA2,316,405 | 2000-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001090361A2 WO2001090361A2 (en) | 2001-11-29 |
WO2001090361A3 true WO2001090361A3 (en) | 2002-08-08 |
Family
ID=25681785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2001/000741 WO2001090361A2 (en) | 2000-05-26 | 2001-05-25 | Modulation of inflammation by protease-treated mcp-3 chemokine |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001261971A1 (en) |
CA (1) | CA2316405A1 (en) |
WO (1) | WO2001090361A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006751A1 (en) * | 1996-08-16 | 1998-02-19 | Research Corporation Technologies, Inc. | Mcp-3, rantes and mip-1alpha receptor antagonists |
EP0905241A1 (en) * | 1997-09-29 | 1999-03-31 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated c-c chemokines as chemokine antagonists |
-
2000
- 2000-08-17 CA CA002316405A patent/CA2316405A1/en not_active Abandoned
-
2001
- 2001-05-25 WO PCT/CA2001/000741 patent/WO2001090361A2/en active Application Filing
- 2001-05-25 AU AU2001261971A patent/AU2001261971A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006751A1 (en) * | 1996-08-16 | 1998-02-19 | Research Corporation Technologies, Inc. | Mcp-3, rantes and mip-1alpha receptor antagonists |
EP0905241A1 (en) * | 1997-09-29 | 1999-03-31 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated c-c chemokines as chemokine antagonists |
WO1999016876A1 (en) * | 1997-09-29 | 1999-04-08 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated mcp-2 as chemokine antagonists |
Non-Patent Citations (5)
Title |
---|
CLARK-LEWIS I ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF CHEMOKINES", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 57, no. 5, 1 May 1995 (1995-05-01), pages 703 - 711, XP000569546, ISSN: 0741-5400 * |
DAMME VAN J ET AL: "STRUCTURAL AND FUNCTIONAL IDENTIFICATION OF TWO HUMAN, TUMOR- DERIVED MONOCYTE CHEMOTACTIC PROTEINS (MCP-2 AND MCP-3) BELONGING TO THE CHEMOKINE FAMILY", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 176, 1 July 1992 (1992-07-01), pages 59 - 65, XP000673185, ISSN: 0022-1007 * |
GONG J-H ET AL: "RANTES AND MCP-3 ANTAGONISTS BIND MULTIPLE CHEMOKINE RECEPTORS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 18, 3 May 1996 (1996-05-03), pages 10521 - 10527, XP002017746, ISSN: 0021-9258 * |
MCQUIBBAN G ANGUS ET AL: "Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.", SCIENCE (WASHINGTON D C), vol. 289, no. 5482, 18 August 2000 (2000-08-18), pages 1202 - 1206, XP002182216, ISSN: 0036-8075 * |
OPDENAKKER G ET AL: "Human monocyte chemotactic protein-3 (MCP-3): Molecular cloning of the cDNA and comparison with other chemokinesfactor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 191, no. 2, 15 March 1993 (1993-03-15), pages 535 - 542, XP002133948, ISSN: 0006-291X * |
Also Published As
Publication number | Publication date |
---|---|
AU2001261971A1 (en) | 2001-12-03 |
WO2001090361A2 (en) | 2001-11-29 |
CA2316405A1 (en) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1600042I1 (en) | Therapeutic use of anti-CS1 antibodies | |
DE60028970D1 (en) | AT HER2 BINDING PEPTIDE COMPOUNDS | |
WO2005102387A3 (en) | Therapeutic use of anti-cs1 antibodies | |
WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
GB0222495D0 (en) | Compounds | |
MXPA02012434A (en) | Antibodies that immunospecifically bind to blys. | |
WO2001043732A3 (en) | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies | |
EP1178988A4 (en) | Compounds and therapeutic methods | |
NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
WO2002067771A3 (en) | Chemokine receptors and disease | |
MXPA02000680A (en) | Vgf polypeptides and methods of treating vgf-related disorders. | |
WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
WO2001090361A3 (en) | Modulation of inflammation by protease-treated mcp-3 chemokine | |
IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
WO2003020221A3 (en) | Method of treating cancerous disease | |
IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence | |
WO2002076405A3 (en) | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions | |
EA200600987A1 (en) | APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS | |
WO2003034069A3 (en) | Tcmp 03 protein for use in cancer therapy | |
WO2001041703A3 (en) | Method for treating allergic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |